The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient. During the comprehensive geriatric assessment realized before the decision-treatment, the following data are recorded and their impact in the therapeutic changes will also be analysed: comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
48
CHD Vendée La Roche sur Yon
La Roche-sur-Yon, France
CHU de Nantes
Nantes, France
The occurrence of the events
The primary outcome is either : * early interruption of treatment * dose reduction \> 20% during treatment * discontinuous treatment These outcomes will be measured every 6 months during the 2 years of follow up
Time frame: 6 MONTHS
Type of Vulnerability
vulnerability related to toxicities, vulnerability related to multiple myeloma or geriatric vulnerability.
Time frame: 6 MONTHS
Therapeutic changes
early interruption of treatment, dose reduction during treatment, discontinuous treatment
Time frame: 6 MONTHS
Toxicity during treatment
hematologic toxicity, neurotoxicity, gastrointestinal toxicity, deep vein thrombosis, pulmonary embolism, infections with antibiotic use
Time frame: 6 months
Progression to 1 and 2 years
Time frame: 1 year/2year
Complete response at 1 and 2 years
Time frame: 1 year/2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.